BSR Annual Conference


As usual members of the BSRBR-RA team will be at the conference to present our research and keep you up to date with all the goings on of the BSRBR-RA.

Where to catch us…

Presentations – Tues 1st May


13.15 – 14.15: Latest project news from the BSR Biologics Registers

 Followed by

14.15 – 15-45: BSR Biologics Registers: a scientific update


Posters – Exhibition hall


Tue 1st May, no. 87

Refractory disease in rheumatoid arthritis: results from the British Society of Rheumatology Biologics Register for rheumatoid arthritis.  This poster will also be part of the Editor’s picks poster tour, Tues 1st May, 10.30-11.30

Thurs 3rd May, no. 243. 

Long-term risk of serious infections in patients with rheumatoid arthritis treated with rituximab: five year data from the British Society of Rheumatology Biologics Register for rheumatoid arthritis

Thurs 3rd May, no. 241. 

Profiling rheumatoid arthritis biosimilar switchers: data from the British Society of Rheumatology Biologics Register for rheumatoid arthritis. 


Biologics Registers Stand


Come along and say hello to members of our team at our stand.  We will have lots of information updates and our team are also eager to answer any questions you have about the register!



Annual Statements & BSRBR-RA Contributors

Annual statements will be arriving soon; these will update how your centre is doing in terms of recruitment and follow up. Please remember to update us with contact details and get in touch with any queries you have about your statement.

Annual Statement 2017

Now is also a good time to make sure those involved with the collecting of data at your centre are included on our contributors list.  This is a list of ALL rheumatologists/ nurses/ allied health professionals who have EVER contributed clinical date to the BSRBR-RA since it began in 2001.

There will be a form included with your statement or you can access this via the website and view the current list HERE.


Recruitment News

You can now register patients with RA starting, or switching to, a number of new products including Olumiant (baricitinib), Kevzara (sarilumab), Rixathon (rituximab), Erelzi (etanercept) and Xeljanz (tofacitinib).

Updated eligibility table, checklist, re-registration guide and recruitment posters are in the process of being sent out to centres, so keep an eye out for this information in the post. Alongside this documents are being circulated electronically (where possible) and of course being made available on our WEBSITE.

Full details of relevant approvals for these new drugs have previously been circulated and can also be found HERE.

recruitment table

If you can’t find the answer to your questions about recruitment on our website please contact the office and we will do our best to help you.

Study News

Centre of the Month

This year we have had over 2000 registrations and received almost 16,000 clinical follow up forms.  Thank you to everyone involved in supporting the register by registering participants, completing our follow-up forms/ information requests and providing this essential data to the register.

November centre of the month awards go to:

Actemra (tocilizumab) recruitment – Queen Elizabeth Hospital, Kings Lynn

Biosimilar & Total recruitment – Nottingham University Hospital NHS Trust (QMC)

Well done to our top recruiters and keep up the good work everyone.


Office News

The BSRBR-RA offices will be closed from Friday 22nd December and reopening Wednesday 3rd January 2018.  We are sorry but we will not be available during this time to answer your queries (but we won’t be sending you any new paperwork either).  Any emails or messages left for us will be dealt with upon our return in the New Year.

Merry Christmas from the BSRBR-RA Team.


PARTICIPANT UPDATE – Frequently Asked Questions

1 – What is data linkage?

data flow

The data that we collect from participants or their doctors  can be enhanced by linking to other national healthcare databases such as those held by NHS Digital (such as healthcare data from the Office for National Statistics). This means that we can be informed when health events happen that we might have not previously known about via participants or the hospitals.

The current BSRBR-RA participant information sheet has full details of what is involved in linking to other national healthcare databases.  If when you joined the register you signed version 8 of the consent form (dated 19/10/2016) or any subsequent version you will have already seen this information. However if you joined the study before this time, then you may want to read further details around this linkage.

You can see a copy of the information sheet HERE.

2 – What if I decide I don’t want to take part anymore?


Please remember that you are able to withdraw from the study at any time should you wish to do so and this will not affect your standard of care in any way.  Not every withdrawal needs to be complete, for example if you choose not to fill in forms yourself but have your rheumatology consultant continue to provide the study with information.  Again further details can be found on our website or by contacting us direct at the office.

For further details on the above see our Protecting Data Information page HERE.

Centre of the Month

These little bears have recently taken up temporary residence in our offices.  Can your recruitment impress us enough to get one a new home on your desk?  Keep sending us those registrations and we hope to be announcing bear winners soon.

Recent Centre of the Month winners:


Biosimilar & Total recruitment – Ipswich Hospital NHS Trust

Cimzia recruitment – Cannock Chase Hospital


Biosimilar & Total recruitment – Nottingham University Hospital NHS Trust (QMC)

Anti-TNF recruitment – Royal Free Hospital

Cimzia recruitment – Kings College Hospital

Keep up the good work and remember to keep an eye out for announcements regarding new therapies joining the register soon!

Research News: ACR Annual Meeting

ACR 2017

Are you lucky enough to be leaving the chilly UK and heading to the ACR/ARHP Annual Meeting in sunny San Diego?  Our researchers have poster presentations on “Long-Term Risk of Serious Infections in Patients with Rheumatoid Arthritis Treated with Rituximab” (abstract 547) & “Refractory Disease in Rheumatoid Arthritis” (abstract 141) in ACR Poster Session A (Sun 5th, 9-11 am).  And “Switching from RA Originator to Biosimilar in Routine Clinical Care” (abstract 2439) in ACR Poster Session C (Tue 7th, 9-11 am).  Check them out if you are there.